Press release
Castle Biosciences Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii®
FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care,
About this update from Castle Biosciences, Inc.
[{"type":"text","content":"\n \n\n\n FRIENDSWOOD, Texas--(BUSINESS WIRE)--\nCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will present new data across its dermatologic portfolio of commercially available and pipeline gene expression profile (GEP) tests at the 2024 Winter Clinical Dermatology Conference - Hawaii, being held Jan. 12-17 in Honolulu, Hawaii.\n\n\n“We are committed to challenging current disease management paradigms and building the evidence supporting our portfolio of clinically actionable molecular tests and their use to improve decision-making for patients with skin cancers and inflammatory skin diseases,” said Robert Cook, Ph.D., senior vice president of research and development at Castle Biosciences. “As such, we are proud to share our latest data at Winter Clinical – Hawaii in collaboration with leading physicians who we believe share our vision of transforming the management of these potentially serious diseases.”\n\n\nHighlights from Castle’s posters at Winter Clinical – Hawaii are included below. Posters will be displayed for viewing in the Coral Ballroom 2 through Jan. 16 at 1 p.m. Hawaii Standard Time.\n\n\nDecisionDx-Melanoma\n\n\n\nReal-world evidence confirms risk stratification of the 31-GEP and i31-GEP in prospectively tested patients with stage I-III cutaneous melanoma\n\n\n\nSummary: To further advance personalized patient care, Castle’s DecisionDx-Melanoma test result, based on a patient’s tumor biology, was integrated with clinical and pathological factors using a validated proprietary algorithm (i31-GEP for risk of recurrence, or ROR). The i31-GEP ROR provides a more personalized, precise risk of tumor recurrence to guide clinical management of CM. This study aimed to validate the DecisionDx-Melanoma test and i31-GEP ROR algorithm in a real-world cohort of patients with stage I-III CM (n=1,831) who received the DecisionDx-Melanoma test as part of their routine clinical care. The study confirmed the independent and significant risk-stratification provided by DecisionDx-Melanoma and its integrated i31-GEP ROR algorithm, identifying patients at high risk of melanoma recurrence to guide important, risk-appropriate interventions, such as imaging surveillance and immunotherapy, that can potentially improve patient outcomes.\n\n\n\nView poster here.\n\n\n\nDe...